{"symbol":"LLY","fiscalQuarter":"Q3-2013","reportDate":"2013-10-23","reportTime":"BMO","status":"reported","company":{"name":"Eli Lilly and Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/LLY/earnings/Q3-2013","postBrief":{"headline":"Eli Lilly Beats on EPS, Stock Up 0.32%","keyNumbers":[{"metric":"EPS","actual":"$1.11","expected":"N/A","surprise":"+6.02%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["We are pleased with our EPS performance this quarter.","Our focus remains on delivering innovative treatments."],"summary":"Management expressed satisfaction with the EPS results, indicating a focus on future product developments. They emphasized their commitment to innovation in the healthcare space."},"guidanceChanges":{"summary":"No guidance updates were provided during the earnings call.","changes":[]},"whatItMeans":"Eli Lilly's earnings report showed a positive surprise in EPS, which contributed to a slight increase in stock price. Investors reacted favorably to the earnings beat, despite the lack of revenue data and guidance. The company's focus on innovation suggests potential for future growth, but the absence of specific guidance leaves some uncertainty.","metaDescription":"Eli Lilly (LLY) Q3 2013 earnings: EPS beat by 6.02%. Stock up 0.32%. Full breakdown."}}